4s3 Bioscience (Medford, MA) a preclinical-stage biotherapeutics company focused on developing genetics disease therapies for orphan neuromuscular disorders, closed a $20M Series A financing. Participants include KLP Enterprises. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $3.5M Series B financing. Participants include Parinvest Capital, La Financiere Gaspard and Truffle Capital Thanx for your patience as we catch-up.